F-star Therapeutics, Inc.

Practice Area: 
Stock Symbol: 
Case Status: 

Ademi LLP is investigating F-star (NASDAQ:FSTX) for possible breaches of fiduciary duty and other violations of law in its transaction with invoX.

Ademi LLP alleges F-star’s financial outlook and prospects are excellent and yet F-star holders will receive only $7.12 per share. The acquisition values F-star at approximately $161 million. The transaction agreement unreasonably limits competing bids for F-star by imposing a significant penalty if F-star accepts a superior bid. F-star insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of F-star’s board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for F-star.